Cover Image
Market Research Report

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H1 2018

Published by Global Markets Direct Product code 358352
Published Content info 56 Pages
Immediate Delivery Available
Price
Back to Top
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H1 2018
Published: March 6, 2018 Content info: 56 Pages
Description

Summary:

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Nociceptin receptor also known as the nociceptin or orphanin FQ receptor or kappa-type-3 opioid receptor is a protein encoded by the OPRL1 (opioid receptor-like 1) gene. NOP receptors are located both pre- and post-synaptically in various areas of CNS. The nociceptin receptor (NOP) and its endogenous ligand, nociceptin are involved in biological functions, such as pain, anxiety, learning, and memory.

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 7 and 1 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Immunology which include indications Dyskinesia, Substance (Drug) Abuse, Chronic Pain, Neuropathic Pain, Pain, Acute Pain, Alcohol Addiction, Bladder Pain, Cancer Pain, Diabetic Neuropathic Pain, Drug Addiction, Hypersensitivity, Inflammatory Pain, Low Back Pain, Major Depressive Disorder, Osteoarthritis Pain, Parkinson's Disease, Post-Traumatic Stress Disorder (PTSD), Pulmonary Arterial Hypertension and Systolic Hypertension.

The latest report Nociceptin Receptor - Pipeline Review, H1 2018, outlays comprehensive information on the Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)
  • The report reviews Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC1341TDB

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Overview
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Companies Involved in Therapeutics Development
  • Blackthorn Therapeutics Inc
  • Grunenthal GmbH
  • Orexigen Therapeutics Inc
  • Serodus ASA
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Drug Profiles
  • AT-076 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AT-089 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AT-127 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AT-200 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AT-212 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AT-326 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AT-403 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BTRX-246040 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cebranopadol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GRT-6010 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OREX-1038 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptides to Agonize ORL1 for Acute Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SER-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize Nociceptin Receptor for Post Traumatic Stress Disorder - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Dormant Products
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Discontinued Products
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 07, 2017: BlackThorn Therapeutics Presents Preclinical and Clinical Data from Its First-in-Class NOPR Antagonist at American College of Neuropsychopharmacology Annual Meeting
  • Jul 24, 2017: BlackThorn Therapeutics Enrolls First Patient in Phase 2a Study of Lead Compound, BTRX-246040, in Major Depressive Disorder
  • Jul 10, 2017: Orexigen Announces Presentation of Preclinical Data for OREX-1038 at the International Narcotics Research Conference
  • Jan 05, 2017: Orexigen Therapeutics Provides Update on OREX-1038 at 35th Annual J.P. Morgan Healthcare Conference
  • Dec 19, 2016: Serodus: Novel article on SER100 in patients with isolated systolic hypertension is published in Journal of Clinical Pharmacology in Drug Development
  • Oct 25, 2016: Orphan drug designation for SER100 in Pulmonary Arterial Hypertension granted in U.S.
  • Sep 30, 2016: Grunenthal's cebranopadol, a novel strong analgesic, meets primary efficacy endpoint in Phase 3 trial in cancer pain
  • Aug 09, 2016: NIH Grant Will Fund Development of Small Molecules for Post-Traumatic Stress Disorder
  • May 23, 2016: Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Potential and a Favorable Respiratory Profile
  • Apr 18, 2016: PCT SER100 patent application filed - Serodus demonstrates a novel mechanism of action in Pulmonary Hypertension
  • Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms
  • Apr 20, 2015: Provisional patent application filed for the Orphan Diseases of Pulmonary Hypertension
  • Sep 15, 2014: Serodus announces details on the clinical study of SER100 in patients with systolic hypertension
  • Sep 09, 2014: Serodus Announces Positive Phase IIa Clinical Study Results On SER100 In Patients with Systolic Hypertension
  • Jun 23, 2014: Serodus Completes The Enrollment Of Patients In Phase IIa Study
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indication, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Blackthorn Therapeutics Inc, H1 2018
  • Pipeline by Grunenthal GmbH, H1 2018
  • Pipeline by Orexigen Therapeutics Inc, H1 2018
  • Pipeline by Serodus ASA, H1 2018
  • Dormant Projects, H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top